On July 19, 2006, the FDA issued a Public Health Advisory for SSRIs, including Celexa (citalopram), Fluvoxamine, Lexapro (escitalopram), Symbyax (olanzapine and fluoxetine) and Zoloft (sertraline) based on a study that suggests there may be additional risks of SSRI medications during pregnancy. In this study, PPHN (Persistent pulmonary hypertension of the newborn) was six times more common in babies whose mothers took an SSRI antidepressant after the 20th week of the pregnancy compared to babies whose mothers did not take an antidepressant.
Baum, Hedlund, Aristei & Goldman and Robinson Calcagnie Robinson Shapiro Davis, Inc. (RCRSD) are working together to prosecute the firms’ antidepressant birth defects and PPHN cases. Both law firms are recognized preeminent plaintiff firms in the forefront of antidepressant litigation. Our attorneys have successfully handled over 3,000 SSRI-antidepressant cases in the past two decades.